Lavaca Capital LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 59.4% during the 1st quarter, HoldingsChannel reports. The firm owned 1,198 shares of the company’s stock after selling 1,754 shares during the quarter. Eli Lilly and Company comprises 0.5% of Lavaca Capital LLC’s holdings, making the stock its 29th biggest position. Lavaca Capital LLC’s holdings in Eli Lilly and Company were worth $932,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $5,992,890,000. International Assets Investment Management LLC grew its stake in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the last quarter. Sapient Capital LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $682,139,000. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after acquiring an additional 1,133,810 shares during the last quarter. Finally, GQG Partners LLC grew its stake in shares of Eli Lilly and Company by 20.2% in the first quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock worth $2,994,280,000 after acquiring an additional 648,094 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. Bank of America reaffirmed a “buy” rating and issued a $1,000.00 target price on shares of Eli Lilly and Company in a research report on Monday, June 24th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Finally, Citigroup raised their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $858.72.
Insider Buying and Selling
In related news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Insiders sold a total of 1,214,704 shares of company stock worth $1,066,841,316 over the last three months. 0.13% of the stock is currently owned by company insiders.
Eli Lilly and Company Price Performance
Shares of Eli Lilly and Company stock traded up $3.17 during trading on Monday, reaching $807.79. The company’s stock had a trading volume of 2,453,380 shares, compared to its average volume of 2,985,220. The stock has a 50-day moving average price of $870.62 and a two-hundred day moving average price of $785.24. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a one year low of $446.89 and a one year high of $966.10. The stock has a market capitalization of $767.73 billion, a P/E ratio of 118.97, a price-to-earnings-growth ratio of 1.75 and a beta of 0.41.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue was up 26.0% on a year-over-year basis. During the same period last year, the company earned $1.62 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.79 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s payout ratio is 76.58%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- How to Invest in the Best Canadian StocksĀ
- Survey: Top 175 Fittest Retirement Locations in America
- Why is the Ex-Dividend Date Significant to Investors?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.